Part II of this 7,000-patient trial suffered from discontinuations and low event rates: still, early MRA did not impact CV ...

The two strategies, used to reduce renal, brain, and heart injury after surgery, were ineffective, but the story isn’t done.

CHICAGO, IL—For patients with a history of acute MI who are vulnerable to the cardiovascular risks posed by influenza ...

CHICAGO, IL—Following bioprosthetic valve surgery, anticoagulation with edoxaban (Savaysa; Daiichi Sankyo) is as effective as ...

HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...

The prevalence of obesity and overweight is extraordinarily high. Unsurprisingly, deaths related to obesity are on the rise, ...

Clinicians typically first turn to antiarrhythmic drugs, but switching up the order may be offer patients better outcomes.

The improved engagement with HF patients intended to optimize GDMT was very modest, but did lead to increased use of MRAs.

CHICAGO, IL—Giving rivaroxaban (Xarelto; Bayer/Janssen) to adults under the age of 65, after an atrial fibrillation (AF) ...

Amidst discrepant SPRINT and ACCORD data, this study confirms the benefits seen in nondiabetics, Shawna Nesbitt says.

There’s no “silver bullet” for this problem, which is largely driven by clinical inertia, but some efforts are chipping away ...

COVID-19 “magnified” preexisting disparities for rural patients as compared with their urban counterparts, one study author ...